AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 42 min read$EVMN

Pena Luis C. sold $382K of EVMN

Pena Luis C. (President & CEO) sold 16,787 shares of Evommune, Inc. (EVMN) at $22.74 ($0.38M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Pena Luis C.
Published Jun 4, 2026, 12:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 12:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EVMN
Neutral
medium confidence
Mentioned
$EVMN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EVMNNeutralLow
01

Why it matters

This disclosure provides a datapoint on insider behavior but does not, by itself, confirm new company fundamentals; the presence of a 10b5-1 plan typically lowers interpretive weight.

02

Market read

Insider selling may cause short-lived sentiment drift, but traders should treat it as low-signal given the pre-arranged nature of the sale.

03

What to watch

Traders should check whether there are concurrent insider buys/sales or subsequent filings that could clarify whether this is part of a broader pattern.

Relevance 7/10Novelty 6/10Timing: SEC Form 4 filed June 3 for a sale executed June 1

Background

The article summarizes an SEC Form 4 insider transaction for Evommune, Inc. (EVMN) by its President & CEO, including trade size, price, and post-sale holdings.

Company-level read

Ticker impact

$EVMNNeutralMedium confidence
Context

Evommune CEO sold 16,787 shares in an open-market transaction under a pre-arranged 10b5-1 plan, reducing insider exposure.

Expected impact

Likely limited near-term impact; any reaction should fade unless accompanied by other fundamentals.

Evidence & confidence

The filing is a routine 10b5-1 sale with no accompanying operational or financial catalyst in the article.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.

Key entities

  • issuer
    Evommune, Inc.

    Subject of the insider transaction disclosure (SEC Form 4) involving its President & CEO.

  • insider
    Pena Luis C.

    President & CEO who sold shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EVMN insider trading history →

Related articles

SEP 9
$EVMNHighAI 9/10

Why is Evommune stock sliding 13% today?

Evommune's stock fell 13.9% to $11.26 after its EVO756 drug failed Phase 2b trials for atopic dermatitis, marking its second failure this year. The company will not advance the drug for this indication but will continue testing in migraine prophylaxis. Analysts' opinions are divided, with Evercore ISI maintaining a Buy rating. The stock is near its 52-week low, reflecting the setbacks and broader market caution.

investing.com2 min
SEP 9
$EVMNHighAI 8/10

Why is Evommune stock tumbling today?

Evommune's stock fell 16.4% to $10.93 after its drug EVO756 failed Phase 2b trials for atopic dermatitis. The company will not advance the drug for this condition but will continue testing for migraine prophylaxis. This is the second Phase 2b failure for EVO756 in 2026. Evercore ISI maintained a Buy rating, but broader market declines also pressured the stock.

investing.com1 min
SEP 8
$EVMNHighAI 8/10

Why is Evommune stock plunging today?

Evommune Inc (EVMN) stock fell 27.4% to $9.50 in after-hours trading after disappointing Phase 2b results for EVO756 in atopic dermatitis. The company had previously failed a trial for chronic spontaneous urticaria, leading to a downgrade. The S&P 500, Dow Jones, and Nasdaq remained flat, indicating the drop was company-specific. EVMN's stock is now below its 52-week low.

investing.com1 min
SEP 8
$EVMNMedAI 8/10

Evommune stock tumbles after trial misses primary endpoint

Evommune Inc (EVMN) shares dropped 27% after its EVO756 drug failed to meet primary and secondary endpoints in a Phase 2b trial for atopic dermatitis. The trial involved 121 adults over 12 weeks. Evommune will not advance EVO756 for this indication but will continue its development for migraine prophylaxis. The company plans to advance EVO301 for atopic dermatitis, with a Phase 2b trial expected in mid-2027. Evommune reports a strong balance sheet supporting operations into 2029.

investing.com2 min
AUG 6
$EVMNMed

Evommune, Inc. (EVMN): Results of Operations and Financial Condition

Evommune, Inc. (EVMN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights ‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in

SEC EDGAR 8-K4 min